Debiopharm Invests in Diagnoplex to Push Colon Cancer MDx Through Clinical Trials

Diagnoplex received a boost toward commercializing its flagship PCR-based colon cancer blood test in the form of a "substantial" Series A financing extension by fellow Swiss biopharmaceutical conglomerate Debiopharm Group.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.